NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Ensuring accuracy in the development and application of nucleic acid amplification tests (NAATs) for infectious disease
Published
Author(s)
Jim Huggett, Denise O'Sullivan, Simon Cowen, Megan Cleveland, Jacob Moran-Gilad, Amanda Winter, Michael Messenger, Julian Braybrook
Abstract
Diagnostic tests were heralded as crucial during the COVID-19 pandemic with most of the key methods using bioanalytical approaches. Bioanalytical techniques can be loosely described as methods that identify and quantify larger molecules (than conventional clinical biochemistry). For infectious disease diagnosis, this typically describes the detection of the presence of pathogen derived nucleic acids, proteins or the host antibody response to said pathogen. Through genetic analysis, Nucleic Acid Amplification Tests (NAATs), like Polymerase Chain Reaction (PCR), and other molecular methods, like sequencing (that often work in combination with NAATs), enabled the ability to rapidly identify the cause of COVID-19 and provide a diagnostic response within weeks. PCR essentially made a timely response to COVID-19 possible. However, early in the pandemic this testing was largely unstandardised which, in short, meant it was unclear how well the tests were actually working. This meant results that were being used to guide interventions to stop the pandemic were of assumed accuracy. Later in 2020 the WHO published its first target product profile (TPP) outlining requirements for COVID-19 diagnostic tests to support their development and since then TPPs are becoming more commonplace in this sector. The attention placed on molecular diagnostic tests during COVID provides a useful case to aid discussion. In this manuscript we discuss conventional approaches to diagnostic evaluation and explore how they may be better tailored to diagnostic techniques like NAATs to maximise the impact of these highly versatile bioanalytical tools.
Huggett, J.
, O'Sullivan, D.
, Cowen, S.
, Cleveland, M.
, Moran-Gilad, J.
, Winter, A.
, Messenger, M.
and Braybrook, J.
(2024),
Ensuring accuracy in the development and application of nucleic acid amplification tests (NAATs) for infectious disease, Molecular Aspects of Medicine, [online], https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=956935
(Accessed October 6, 2025)